Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3Phase NA 1Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 9INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 3Neoplasms 1Neoplasm Metastasis 1

Interventions

Carboplatin 272Paclitaxel 267Gemcitabine 244Bevacizumab 225Cisplatin 216pembrolizumab 213Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 99Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 80Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Ipilimumab 64Bortezomib 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × tipiracil × Clear all
NCT06992258 2026-03-17

FRUITION

Criterium, Inc.

Phase 2 Recruiting
120 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT02743221 2024-08-20

TASCO1

Servier

Phase 2 Completed
154 enrolled 15 charts
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT04854434 2023-11-03

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

Karyopharm Therapeutics Inc

Phase 2 Terminated
13 enrolled 14 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡